Abstract: An agent for the prevention and treatment of inflammatory bowel disease (IBD) containing at least one of zinc L-carnosine salts and complexes as an active ingredient. A use of the zinc L-carnosine salts or complexes and a therapeutic method of IBD by using the same are also disclosed.

Abstract: There are provided quaternary ammonium compounds of the formula: ##STR1## wherein R.sub.1 and R.sub.2, each independently represents a hydrogen atom, a C.sub.1 to C.sub.8 lower alkyl or alkenyl group, or C.sub.3 to C.sub.8 lower cycloalkyl, cycloalkenyl, aralkyl or aryl group; or R.sub.1 and R.sub.2 combine with each other in combination with the adjacent N and carbon atoms or further with at least one of nitrogen, oxygen and sulfur atoms to represent a 3- to 8- membered heterocyclic ring group: R.sub.3, R.sub.4 and R.sub.5, each independently represents a C.sub.1 to C.sub.8 lower alkyl or alkenyl group, C.sub.3 to C.sub.8 lower cycloalkyl, cycloalkenyl, aralkyl or aryl group; or either two of R.sub.3, R.sub.4 and R.sub.5 combine with each other in combination with the adjacent N and carbon atoms or further with at least one of nitrogen, oxygen and sulfur atoms to represent a 3- or 8-membered heterocyclic ring group, with the remaining being the same as defined in the above; or R.sub.3, R.sub.4 and R.sub.

Abstract: There is provided an oral antihepatopathic composition comprising protoporphyrin IX-Zn(II) complex. By oral administration, the complex can suppress the elevation of GPT and GOT as well as the increase of liver weight in a living body suffering from hapatic disorder, which contributes to prevention or relief of the disease.

Abstract: A novel crystalline L-carnosine zinc complex is produced by reacting L-carnosine, a zinc salt and an alkali metal compound in an anhydrous or hydrous polar organic solvent.The crystalline L-carnosine zinc complex substantially corresponds to the formula C.sub.9 H.sub.12 N.sub.4 O.sub.3 Zn and has physical properties clearly different from the known amorphous L-carnosine zinc complex.As compared with the amorphous complex, the crystalline complex is very low in impurity, stable to heat and moisture, and easy to filtrate, and has higher anti-ulcer activity.

Abstract: There are provided acetamide compounds represented by the following formula; ##STR1## wherein R.sub.1 and R.sub.2 each independently represents a hydrogen atom, a C.sub.1 to C.sub.6 straight- or branched-chain alkyl or alkenyl group, a C.sub.3 to C.sub.6 cycloalkyl or cycloalkenyl group, or a C.sub.6 to C.sub.10 aromatic group; or R.sub.1 and R.sub.2 combine with each other in combination with the adjacent N and carbon atoms or further with at least one of nitrogen, oxygen and sulfur atoms to represent a 5- to 6-membered heterocyclic ring group; R.sub.3 represents hydrogen atom, a C.sub.1 to C.sub.6 straight- or branched-chain alkyl or alkenyl group, a C.sub.3 to C.sub.6 cycloalkyl or cycloalkenyl group, a halogen atom, a C.sub.1 to C.sub.6 straight- or branched-chain alkyloxy group, or a C.sub.3 to C.sub.6 cycloalkyloxy or cycloalkenyloxy group; and n is an integer of 1 to 4, and their pharmaceutically acceptable salts.

Abstract: A new preventive and therapeutic agent given by oral administration containing carnosine zinc salt as the effective component and, effective against alcoholic liver disorder, viral hepatitis or liver disorders caused by drugs, toxicants, radiation, etc.